3,977 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,977 shares of the medical research company’s stock, valued at approximately $505,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Cerity Partners LLC raised its stake in shares of Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after buying an additional 85,236 shares during the last quarter. King Luther Capital Management Corp increased its stake in Natera by 0.6% in the 3rd quarter. King Luther Capital Management Corp now owns 30,036 shares of the medical research company’s stock valued at $3,813,000 after buying an additional 192 shares during the period. Advisors Asset Management Inc. raised its position in Natera by 17.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,778 shares of the medical research company’s stock worth $607,000 after buying an additional 714 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Natera in the 3rd quarter worth $9,157,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Natera

In related news, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares of the company’s stock, valued at $36,324,409.37. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the transaction, the director now owns 19,386 shares in the company, valued at $3,073,262.58. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,503 shares of company stock worth $6,325,804. 7.60% of the stock is currently owned by company insiders.

Natera Price Performance

NTRA stock opened at $167.26 on Friday. Natera, Inc. has a one year low of $53.62 and a one year high of $171.95. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $22.08 billion, a PE ratio of -95.03 and a beta of 1.53. The firm has a 50-day moving average of $131.54 and a two-hundred day moving average of $117.85.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the company earned ($0.95) earnings per share. The company’s revenue was up 63.9% compared to the same quarter last year. On average, analysts forecast that Natera, Inc. will post -1.66 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Robert W. Baird boosted their target price on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler raised their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. UBS Group dropped their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.